A detailed history of Jpmorgan Chase & CO transactions in Cybin Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 305 shares of CYBN stock, worth $3,046. This represents 0.0% of its overall portfolio holdings.

Number of Shares
305
Previous 1,034 70.5%
Holding current value
$3,046
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$0.26 - $0.46 $189 - $335
-729 Reduced 70.5%
305 $0
Q4 2023

Feb 12, 2024

BUY
$0.38 - $0.65 $277 - $473
729 Added 239.02%
1,034 $0
Q3 2023

Nov 14, 2023

BUY
$0.29 - $0.63 $88 - $192
305 New
305 $0
Q4 2022

Feb 13, 2023

BUY
$0.26 - $0.64 $520 - $1,280
2,000 Added 12.5%
18,000 $5,000
Q3 2022

Nov 14, 2022

BUY
$0.48 - $1.11 $7,533 - $17,421
15,695 Added 5145.9%
16,000 $48,000
Q2 2022

Aug 11, 2022

BUY
$0.41 - $0.88 $125 - $268
305 New
305 $1,000

Others Institutions Holding CYBN

About CYBIN INC.


  • Ticker CYBN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 166,120,000
  • Market Cap $1.66B
  • Description
  • Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...
More about CYBN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.